May 22 (Reuters) - Biogen said on Wednesday it
had agreed to buy privately held Human Immunology Biosciences
for $1.15 billion in upfront and up to $650 million in potential
milestone payments.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj
Kalluvila)